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Summary
Background Exposure and Response Prevention (ERP) is a form of behavioural therapy for tics; however, its 
effectiveness remains uncertain. We aimed to evaluate the effectiveness of internet-delivered, therapist-supported, 
and parent-assisted ERP for treatment of tics in children and young people with Tourette syndrome or chronic tic 
disorder.
Methods This multicentre, parallel group, single-blind, randomised controlled trial was conducted across two study 
sites in England. Participants were recruited via 16 patient identification centres, two study sites in England 
(Nottingham and London), or online self-referral. Eligible participants were aged 9–17 years, had Tourette 
syndrome or chronic tic disorder, had not received behavioural therapy for tics in the past 12 months or were about 
to start, and had a Yale Global Tic Severity Scale (YGTSS) Total Tic Severity Score (TTSS) of more than 15 or more 
than 10 if they had only motor or vocal tics. Patients were excluded if they had started or stopped medication for 
tics within the past 2 months; had current alcohol or substance dependence, psychosis, suicidality, anorexia 
nervosa, or suspected moderate to severe intellectual disability; or presented an immediate risk to self or others; or 
the parent or carer was unable to speak, read, or write in English. Eligible patients were randomly assigned (1:1) by 
masked outcome assessors to receive 10 weeks of online, remotely delivered, therapist-supported ERP or 
psychoeducation (active control). Outcome assessors, statisticians, health economists, the trial manager, and the 
chief investigator were masked to group allocation. Patients were not directly informed of their allocation, but this 
could be established from the content once treatment commenced and the patients were not, therefore, considered 
masked to treatment. The primary outcome was YGTSS-TTSS 3 months after randomisation, and analysis was 
done in all randomised patients for whom data were available for each timepoint and outcome. Safety analysis was 
by intention to treat. Longer term follow-up is ongoing. This trial is registered with ISRCTN (ISRCTN70758207) 
and ClinicalTrials.gov (NCT03483493).
Findings Between May 8, 2018, and Sept 30, 2019, we assessed 445 candidates for inclusion in the study. 
221 potential participants were excluded (90 did not meet inclusion criteria, 84 declined to participate, and 
47 unable to contact family). 224 participants were enrolled and randomly assigned to ERP (n=112) or 
psychoeducation (n=112). The enrolled patients were mostly male (n=177; 79%) and of White ethnicity (n=195; 
87%). 11 patients were lost to follow-up 3 months after randomisation in the ERP group, compared with 12 patients 
in the psychoeducation group. Mean YGTSS-TTSS at 3 months after randomisation was 23·9 (SD 8·2) in the ERP 
group and 26·8 (7·3) in the psychoeducation group. The mean total decrease in YGTSS-TTSS at 3 months was 4·5 
(16%, SD 1·1) in the ERP group versus 1·6 (6%, 1·0) in the psychoeducation group. The estimated mean difference 
in YGTSS-TTSS change between the groups adjusted for baseline and site was –2·29 points (95% CI –3·86 to –0·71) 
in favour of ERP, with an effect size of –0·31 (95% CI –0·52 to –0·10). Two serious adverse events occurred 
(one collapse and one tic attack), both in the psychoeducation group, neither of which were related to study 
treatment.
Interpretation ERP is an effective behavioural therapy for tics. Remotely delivered, online ERP with minimal therapist 
contact time represents an efficient public mental health approach to improve access to behavioural therapy for tics in 
children and adolescents.
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license. 
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Introduction
Tic disorders, such as Tourette syndrome or chronic tic 
disorder, are common conditions that affect up to 1% of 
young people.1 Tics can lead to significant impairment 
and isolation2 and often co-occur with other conditions. 
Although there are effective pharmacological treatments 
for tics, these drugs are often associated with side-effects 
including weight gain and cognitive dulling.2 Behavioural 
therapies for tics include Habit Reversal Training (HRT), 
in which patients learn to detect tics and use a competing 
response (an incompatible action) to control them; 
Comprehensive Behavioural Intervention for Tics (CBIT), 
which combines HRT with relaxation, functional analysis, 
and social support; and Exposure and Response 
Prevention (ERP), in which patients learn to suppress 
their tics (response prevention) while tolerating urges to 
tic (exposure). Unlike HRT and CBIT, no competing 
response is trained in ERP, potentially making it easier to 
deliver with minimal therapist input.
Evidence of the effectiveness of behavioural therapy for 
tics is drawn primarily from two large superiority trials of 
CBIT from the USA in children and adolescents,3 and 
adults.4 ERP has been less well evaluated and its 
effectiveness in treatment for tics compared with an 
active control intervention is unknown. One small pilot 
head-to-head comparison5 between ERP and HRT in 
43 participants reported a similar reduction in tic 
symptoms for both treatments but was underpowered to 
show non-inferiority between the treatments.5
Although HRT and CBIT have shown similar effective-
ness to pharmacotherapy,2 and behavioural ther apy is 
recommended as a first line intervention,1,2 it is rarely 
Research in context
Evidence before this study
We searched 21 databases covering medical and health 
(Embase, MEDLINE, PREMEDLINE In-Process and Other 
Non-Indexed Citations and PsycINFO, Cochrane Library, 
Cochrane Central Register of Controlled Trials, Cochrane 
Database of Systematic Reviews, Database of Abstracts of 
Reviews of Effectiveness, and Health Technology Assessment), 
education (Australian Education Index, British Education Index, 
and Education Resources in Curriculum), social care (Applied 
Social Sciences Index and Abstracts [ASSIA], International 
Bibliography of Social Science, Social Sciences Citation Index, 
Social Services Abstracts, Sociological Abstracts, and Web of 
Science), and grey literature (Health Management Information 
Consortium, PsychBOOKS, and PsychEXTRA) for studies 
published in any language from database inception to 
Jan 1, 2013. Additional sources were Allied and Complementary 
Medicine Database, BIOSIS Citation Index, and Cumulative 
Index to Nursing and Allied Health Literature (CINAHL). 
We updated this search in 2014 to include studies published to 
Oct 1, 2014. The search terms comprised subject headings and 
text words for tic* and tourette* to identify populations with 
Tourette syndrome or chronic tic disorder. Searches were 
limited to systematic reviews and randomised controlled trials 
describing interventions. We identified two randomised 
controlled trials of habit reversal training or comprehensive 
behavioural intervention with a total of 133 participants. 
In 2020, we updated the search again with the same criteria for 
studies published to Jan 1, 2020, and found no new trials of 
behavioural interventions for tics in children and adolescents. 
As part of a systematic review of digital health interventions in 
2017, we searched 11 databases (Allied and Complementary 
Medicine, Ovid, MEDLINE, PsychINFO, PsychARTICLES, Embase, 
PubMed, ASSIA, Cochrane Library, CINAHL, and Web of 
Science), with a smaller keyword search of JMIR Publications 
database, for digital health interventions for mental health 
disorders in children and young people published between 
Jan 1, 2013, and Nov 1, 2015. The search strategy collated terms 
and keywords to identify children and young people (eg, child, 
adolescent, or young person), mental health disorders, 
and digital health interventions (eg, internet interventions, 
apps, eHealth). Full search strategy terms and language 
restrictions are available in the 2017 paper. We identified 
30 unique randomised controlled trials of digital mental health 
interventions, with no digital intervention studies identified 
that focused on treatment of tic disorders. As this was a 
planned review of digital health interventions, these searches 
were not updated before the current study. Also in 2017, we did 
a meta-review of scoping, narrative, systematic, 
or meta-analytical reviews investigating the effectiveness of 
digital health interventions for mental health problems in 
children and adolescents. No effective online behavioural 
interventions for tics have been reported.
Added value of this study
To our knowledge, this is the first randomised controlled trial to 
report the clinical efficacy, safety, and costs of therapist and 
parent-supported online Exposure and Response Prevention 
(ERP) behavioural therapy for tics in children aged 9–17 years. 
We showed that this 10-week online ERP intervention was 
highly acceptable, well tolerated, and effective in reducing tics 
3 months after randomisation, compared with a similar 
duration of online psychoeducation. The magnitude of the 
effect on tic reduction was durable, with a slightly greater effect 
3 months after treatment ended (6 months after 
randomisation). Approximately a quarter of the therapist 
contact time is required compared with face-to-face 
behavioural therapy to achieve a similar result.
Implications of all the available evidence
Digitally enabled ERP for tics is an efficient public mental health 
approach to increase the reach of an effective treatment for 
children and adolescents with tic disorders. Further research is 
needed to establish the optimum care pathways for sequencing 
and integration of digital and face-to-face behavioural therapy 
for tics in children and adolescents.
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available. In the UK, a small study found that only one in 
five children and adolescents with tic disorders has 
access to behavioural therapy, and less than half of those 
with access received the recommended number of 
sessions.6 Barriers to access include a shortage of trained 
therapists and therapy being offered only at specialist 
treatment centres, meaning patients must often travel 
long distances. The COVID-19 pan demic has highlighted 
the urgent need to offer cost-effective interventions that 
can be delivered remotely and in digital formats.7
Across various mental health conditions, meta-analyses 
show that online internet-delivered cognitive behavioural 
therapy (CBT) is as efficacious as face-to-face delivery and 
can result in substantial cost-savings.8 Evidence from 
studies9 of internet-delivered CBT with adults suggests 
that therapist-guided online interventions lead to better 
out comes than standalone online CBT. Given the paucity 
of child therapists in this specialty, a more pragmatic 
solution might entail a blended approach of digitally 
enabled therapy in which the core therapeutic content is 
delivered online in a standardised chapter format, but is 
supported asynchronously by a non-specialist therapist 
whose primary role is to promote engagement. A meta-
analysis10 of CBT for anxiety and depression in children 
suggested that parents are also a potentially valuable but 
under-researched resource to support the use of internet-
delivered CBT in children.
Researchers in Sweden developed an online platform 
to provide therapist-supported internet-delivered CBT, 
called BIP (Barninternetprojektet [Child Internet 
Project]). The platform has been used to deliver therapy 
to children with a range of mental health conditions, 
including anxiety and obsessive-compulsive disorder.11,12 
Compared with other conditions, internet delivery of 
therapy for tics has received less interest.13 One small 
pilot study14 using the BIP platform compared 10 weeks 
of therapist-guided, parent-supported HRT against ERP 
in children and adolescents with tics who were followed 
up at 3 months and 12 months after end of treatment. 
The findings indicted that the method of delivery was 
highly acceptable to families. Although this pilot study 
was not designed or powered to evaluate efficacy, the 
results support the feasibility and promise of online ERP 
for treating tics and justify further investigation to assess 
clinical effectiveness and cost-effectiveness. In our study, 
we aimed to evaluate the clinical effectiveness and 
costs of a therapist-supported, parent-assisted, internet-




The Online Remote Behavioural Intervention for Tics 
(ORBIT) trial is a multicentre, parallel group, single-blind, 
randomised controlled trial, done across two Child and 
Adolescent Mental Health Services sites in England. Site 
one (Queen’s Medical Centre, Nottingham) was based in a 
mid-sized city and was a regional centre for tic treatment. 
Site two (Great Ormond Street Hospital, London) was a 
large metropolitan national paediatric centre of excellence. 
The trial had two phases: phase 1 was a per-protocol 
follow-up for 6 months after patient randomisation and 
phase 2 is a naturalistic follow-up for 18 months after 
patient randomisation. We present the findings from 
phase 1.
Ethical and Health Research Authority approval was 
received from North West Greater Manchester Research 
Ethics Committee (18/NW/0079). The published trial 
protocol is available online15 and was approved by an 
independent trial steering committee and data monitoring 
committee. Two substantial amendments were made 
(appendix p 1).
Participants
Eligible participants were aged 9–17 years with a 
moderate or severe tic disorder (Tourette syndrome or 
chronic tic disorder) defined as Yale Global Tic Severity 
Scale (YGTSS)16 Total Tic Severity Score (TTSS) of more 
than 15, or more than 10 if only motor or vocal tics were 
present in the past 7 days. All participants were required 
to have broadband and access to smartphone, desktop 
computer, or laptop computer and the capacity to provide 
informed, written consent.
Participants were excluded if they had engaged in 
structured behavioural intervention for tics (eg, HRT, 
CBIT, or ERP) within the previous 12 months or were 
about to start; started or stopped medication for tics 
within the previous 2 months; had current alcohol or 
substance dependence, psychosis, suicidality, anorexia 
nervosa (assessed via the Development and Well Being 
Assessment [DAWBA]),17 or suspected moderate to severe 
intellectual disability (assessed via Child and Adolescent 
Intellectual Disability Screening [CAIDS-Q]);18 presented 
an immediate risk to self or others; or the child had no 
parent or carer who was able to speak, read, or write in 
English.
Participants were recruited either by referral from 
one of 16 participating Child and Adolescent Mental 
Health Services or community paediatric clinics in 
England and the two study sites, or by self-referral via the 
Tourettes Action website or the study website. The study 
outcome assessors completed an initial telephone 
consultation to establish likely eligibility, and parents 
or carers completed the online DAWBA. Potential 
participants who were deemed eligible after this initial 
screening phase attended a baseline assessment at one of 
the two study sites, at which assessors did further 
eligibility assessments, including YGTSS and CAIDS-Q. 
Written informed consent was obtained from participants 
or their parents or carers before undertaking the baseline 
assessment.
Participants younger than 16 years had parent or 
guardian signed written consent and signed their own 
written assent. Participants aged 16–17 years had parent 
For more on 
Barninternetprojektet see 
http://www.bup.se/bip
See Online for appendix
Articles
874 www.thelancet.com/psychiatry   Vol 8   October 2021
or guardian signed written consent and signed their own 
written consent.
Randomisation and masking
Participants were randomly assigned (1:1) to receive either 
10 weeks of online, remotely delivered, therapist-
supported ERP for tics, or online therapist-supported 
education about tics (referred to as psychoeducation [the 
active control]). Outcome assessors randomly assigned 
par ticipants using a secure web-based randomisation 
system developed by Sealed Envelope and managed by 
Priment Clinical Trials Unit, following specified standard 
operating procedures. Randomisation was stratified by 
study site using block randomisation with varying block 
sizes. Therapists and an independent assessor who did 
not do outcome assessments were informed of the 
allocation via email. The independent assessor verified 
that each participant was assigned to their allocated 
intervention, and no instances of incorrect allocation 
were observed. Outcome assessors, statisticians, health 
economists, the trial manager, and the chief investigator 
were masked to group allocation. Participants were not 
directly informed of their allocation by either the 
researcher or the therapist, but they might have been able 
to establish allocation from the content once treatment 
commenced. Participants were reminded about the 
importance of masking at each follow-up, and breaks of 
allocation concealment were reported to the trial manager. 
All instances would be reviewed by the independent trial 
steering committee and data monitoring committee.
Procedures
Treatments were delivered via the secure online BIP 
platform. Participants and their parent or carers created 
their log-in details at the baseline assessment and set a 
treatment start date within 1 week of random assignment. 
Where possible, participants were briefly introduced to 
their therapist in person at the baseline assessment. 
Preliminary measures were done, including demo-
graphics, Child and Adolescent Service Use Schedule,19 
and Children’s Global Assessment Scale (CGAS),20 
exposure to concomitant interventions and CAIDS-Q (to 
establish eligibility for treatment). We then did the 
YGTSS assessment to establish presence and severity of 
tics as per the protocol inclusion criteria. All researchers 
undertook extensive YGTSS training and supervision 
sessions. Training and supervision were delivered by a 
clinician expert in the delivery and evaluation of the 
primary measures. All researchers had to reach a 
specified level of expertise before initiation of baseline 
assessments. The therapists assigned the participant to 
their allocated treatment and emailed a reminder to log 
in on their start date.
The treatment content has been described elsewhere.15 
In summary, information was presented in chapters, 
which the family (child or adolescent and parent or carer) 
were requested to work through. The therapist aimed to 
have 10–20 minutes contact time with the participants 
(combined contact time with the parent or carer and 
child or adolescent) each week to check progress, 
encourage motivation, and answer questions, but did not 
deliver therapeutic content. Both the ERP intervention 
and the psychoeducation consisted of ten chapters for 
the child or adolescent and ten different chapters for 
parents or carers, designed to be delivered over 10 weeks. 
The therapist provided support for either ERP or 
psychoeducation through asynchronous contact (typically 
delivered via online messages sent through BIP) during 
these 10 weeks.
The internet-delivered ERP intervention was adapted 
from published treatment manuals by Verdellen and 
colleagues.21 Participants were requested first to practise 
controlling their tics for increasingly long periods of time 
(response prevention), and then to deliberately provoke 
the premonitory urges while not releasing any tics 
(exposure and response prevention). All tics were targeted 
at the same time. Specific triggers to provoke the urge to 
tic were identified and used by participants, and then 
used in everyday situations to improve gen eralisability of 
the gains. The psychoeducation com parator focused on 
the history, prevalence, and risk typically associated with 
tic disorders, and advised healthy habits with no 
information on tic control. For both interventions, the 
main treatment information was delivered via ten child-
completed chapters; participants were considered treat-
ment completers if child chapters 1–4 were completed. 
The first four chapters included the active exposure and 
response prevention components of the intervention and 
were thus considered the minimum therapeutic dose. 
The ten parent chapters focused on how best to support 
the child during their treatment.
Therapists (graduate level education) were not required 
to have previous experience in treating tic disorders but 
were trained on the platform and its contents and 
received regular expert supervision.22 As the therapists 
did not deliver active therapeutic content it was not 
necessary to account for potential therapist effects in 
statistical analysis. Participants completed brief online 
measures at 3 weeks and 5 weeks after randomisation, 
and completed online and outcome-assessor rated 
measures at baseline, 3 months, 6 months, 12 months, 
and 18 months after randomisation. All follow-up 
outcome-assessor rated measures were completed rem-
otely, via videoconferencing or telephone.
Outcomes
The primary outcome was tic severity at 3 months after 
randomisation as measured by YGTSS-TTSS, a semi-
structured interview that combines separate scales of 
motor tics (score 0–25) and vocal tics (score 0–25) to 
provide a total score of 0–50, with higher scores indicating 
greater severity. YGTSS-TTSS is the gold standard 
measure of tics and is used widely in clinical practice and 
research. It is freely available in the public domain and 
For more on Sealed Envelope see 
https://www.sealedenvelope.com
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has been translated into many languages. YGTSS-TTSS 
was completed by a masked outcome-assessor. All 
outcome-assessors completed mandatory structured 
training on YGTSS before starting, and agreement with 
an expert rater was assessed every 6 months (appendix 
p 2).
Secondary outcomes were reduction in tic-related 
impairment assessed through the YGTSS impairment 
scale (score 0–50); global assessment of symptom 
improvement measured via the Clinical Global 
Impressions—Improvement scale (CGI-I);23 global 
func tioning assessed via CGAS; and service use using a 
modified version of the Child and Adolescent Service 
Use Schedule to include specific specialist tic disorder 
services and medications. These outcomes were 
measured at baseline, 3 months, and 6 months after 
randomisation, through interviews done by the masked 
outcome assessors with the parent or carer and child or 
young person.
Parents or carers reported secondary outcomes online, 
including measures of general behavioural and emotional 
difficulties (Strengths and Difficulties Questionnaire),24 
generic health-related quality of life (proxy-rated child-
health-utility-9D [CHU9D]),25 and adverse events or side-
effects (modified version of the Hill and Taylor26 
side-effects scale). A parent assessment of tics measured 
via the Parent Tic Questionnaire27 was completed at these 
times and at 5 weeks after randomisation.
Additional outcomes completed online by the child or 
adolescent included generic quality of life by CHU9D and 
a disease-specific measure of quality of life by Child and 
Adolescent Gilles de la Tourette Syndrome Quality of Life 
Scale (C&A-GTS-QOL).28 Two additional measures (Mood 
and Feelings Questionnaire29 and Spence Childhood 
Anxiety Scale)30 were completed by the child or adolescent 
at 5 weeks after randomisation and at baseline, 3 months, 
and 6 months after randomisation. For the purpose of this 
study, a measure of treatment credibility was developed 
and completed online by parent or carer and child or 
adolescent at 3 weeks.15 Premonitory urges were recorded 
at baseline using the Premonitory Urge for Tics Scale.31
Adverse events and side-effects were formally sought 
and recorded at each follow-up by the side-effects scale 
and Mood and Feelings Questionnaire. Participants were 
also encouraged to report adverse effects to their therapist 
or outcome assessor (appendix pp 4–6).
Statistical analysis
Based on findings of other trials,1 we calculated the 
sample size to detect a clinically important average 
difference of 0·5 SDs between ERP and psychoeducation 
with 90% power at p<0·05 (two-sided). When allowing 
for 20% dropout, this required a total sample size of 
220 participants.
Statistical analyses were done using Stata (version 16) 
in line with a predefined statistical analysis plan approved 
by the trial steering committee. Analysis for the primary 
Figure 1: Trial profile
DAWBA=Development and well-being assessment. CAIDS-Q=Child and Adolescent Intellectual Disability Screening 
Questionnaire. YGTSS=Yale Global Tic Severity Scale. *Analysis was done in all randomised patients for whom data 
were available for each timepoint and outcome. Safety analysis was by intention to treat. 
112 assigned to exposure and response
prevention
11 lost to follow-up
5 withdrew consent
6 unable to make contact
101 followed up at 3 months
224 enrolled and randomised
11 excluded
5 sub-threshold CAIDSQ score
1 had behavioural therapy in past 12 months
1 evidence of deliberate self harm not detected by DAWBA
3 sub-threshold YGTSS score
1 did not understand study purpose
93 followed up at 6 months
112 included in intention-to-treat analysis*
8 lost to follow-up
3 withdrew consent
5 unable to make contact
235 attended baseline screening appointment
445 children and adolescents assessed for eligibility
251 referred by self
181 referred by patient identification centres
13 referred by research site
210 excluded
84 declined to participate
46 no reason specified
18 did not want to participate
10 did not want to attend baseline appointment
5 tics not current priority
5 family difficulties or insufficient time
60 did not meet inclusion criteria
21 had behavioural therapy in past 12 months or were
due to start behavioural therapy
11 lived outside of England
8 immediate risk to self or others
7 Tourette or chronic tic disorder diagnosis not fulfilled
5 outside age range
3 recently started new tic medication
2 likely to have moderate or severe intellectual disability
2 had eating disorder
1 had a family member already in the trial
47 unable to make contact with family
19 excluded by DAWBA
18 deliberate self harm
1 eating disorder concerns and hallucinations
112 assigned to psychoeducation
12 lost to follow-up
5 withdrew 
7 unable to make contact
100 followed up at 3 months
93 followed up at 6 months
112 included in intention-to-treat analysis*
7 lost to follow-up
4 withdrew 
3 unable to make contact
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outcome was done on a modifed intention-to-treat basis, 
in which participants were analysed according to their 
allocated group using all available data for a given 
outcome and timepoint. In line with the statistical 
analysis plan, 95% CIs are reported rather than p values. 
Secondary outcomes and duration of response were 
analysed based on number of patients in the intention-
to-treat population who supplied data. Safety analyses 
were done by intention to treat.
Baseline demographic characteristics of participants 
and their clinical and mental health outcomes at 
baseline, 3 months after randomisation, and 6 months 
after randomisation were summarised by randomised 
group using mean (SD) for continuous data or count 
(%) for categorical data. The primary outcome was 
estimated using a linear regression model with YGTSS-
TTSS at 3 months as the outcome and study group as 
the main explanatory variable, adjusting for YGTSS-
TTSS at baseline and site.
Similar linear regression models were fitted to estimate 
the effect of the intervention on secondary outcomes at 
5 weeks, 3 months, and 6 months after random 
assignment. The statistical model for CGI-I did not 
adjust for baseline since this is a measure of change. 
Using CGI-I to indicate response to treatment, the scale 
was dichotomised to define response as improved or 
much improved versus non-response as minimally 
improved, stayed the same, worse, or very much worse. 
Two unplanned subgroup analyses explored whether the 
effect of the intervention on the primary outcome was 
modified by diagnosis of either anxiety or ADHD. The 
statistical models were the same as for the main analysis 
of the primary outcome, with the addition of a fixed effect 
of the comorbidity (anxiety or ADHD) and an interaction 
between the comorbidity and study groups. All statistical 
analyses were by complete case.
A text message notification was sent to the therapist 
every time a participant or parent logged in so they could 
monitor progress and provide support if needed. A 
variable cost was calculated at £0·17 for each SMS 
notification. A separate full economic evaluation will be 
done at 18 months of follow-up (phase 2) as the follow-up 
duration of 6 months is insufficient for calculating an 
incremental cost per quality-adjusted life year (QALY) 
gained. Here we explore the cost of delivering the ERP 
and psychoeducation interventions, examine relevant 
health- care resource use, and evaluate the suitability of 
CHU9D for calculating QALYs in an 18-month analysis. 
Further details on the method and findings can be found 
in the appendix (pp 8–23). The trial was registered 
with ISRCTN (ISRCTN70758207) and ClinicalTrials.gov 
(NCT03483493).
Role of the funding source
The study was funded by the UK National Institute for 
Health Research Health Technology Assessment 
(Ref 16/17/02). The funders had no role in the study 
Psychoeducation (n=112) Exposure and response 
prevention (n=112)
Age at random assignment, years 12·4 (2·1) 12·2 (2·0)
Sex
Male 87 (78%) 90 (80%)
Female 25 (22%) 22 (20%)
Ethnicity
White 99 (88%) 96 (86%)
Asian 3 (3%) 7 (6%)
Black 0 (0%) 1 (1%)
Mixed 7 (6%) 3 (3%)
Other 1 (1%) 0 (0%)
Not given 2 (2%) 5 (4%)
Main caregiver in trial
Mother 101 (90%) 93 (83%)
Father 10 (9%) 16 (14%)
Grandmother 1 (1%) 1 (1%)
Other 0 (0%) 2 (2%)
Mother’s highest educational level
No qualifications 1 (1%) 3 (3%)
Mandatory secondary education (eg, GCSEs) 17 (15%) 16 (14%)
Further education (eg, A-levels, BTEC, NVQ) 32 (29%) 33 (29%)
Higher education (eg, BA, BSc) 46 (41%) 46 (41%)
Postgraduate education (eg, MA, MSc, PhD) 16 (14%) 14 (13%)
Father’s highest educational level
No qualifications 5 (4%) 2 (2%)
Mandatory secondary education (eg, GCSEs) 29 (26%) 29 (26%)
Further education (eg, A-levels, BTEC, NVQ) 33 (29%) 35 (31%)
Higher education (eg, BA, BSc) 34 (30%) 32 (29%)
Postgraduate education (eg, MA, MSc, PhD) 11 (9%) 14 (13%)
Mother’s occupational status
Not in work or unemployed 22 (20%) 19 (20%)
Manual or semimanual occupation 26 (23%) 24 (21%)
Professional occupation 57 (51%) 65 (58%)
Other 7 (6%) 4 (4%)
Father’s occupational status
Not in work or unemployed 4 (4%) 2 (2%)
Manual or semimanual occupation 30 (27%) 33 (29%)
Professional occupation 67 (60%) 65 (58%)
Other 10 (9%) 12 (11%)
Tic types
Both motor and vocal tics 106 (95%) 103 (92%)
Motor tics only 6 (5%) 9 (8%)
Vocal tics only 0 (0%) 0 (0%)
Comorbidities*
Anxiety disorder† 27 (24%) 34 (30%)
ADHD 25 (22%) 26 (23%)
Oppositional defiant disorder 23 (21%) of 111 26 (24%) of 110
Autism spectrum disorder 4 (4%) 9 (8%) of 111
Obsessive compulsive disorder 3 (3%) 8 (7%)
Major depression 6 (5%) 2 (2%)
Conduct disorder 2 (2%) of 111 3 (3%) of 110
(Table 1 continues on next page)
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design, data collection, data analysis, data interpretation, 
writing of the report, or the decision to submit the 
paper for publication.
Results
Between May 8, 2018, and Sept 30, 2019, we assessed 
445 potential participants for inclusion in the study. 
210 were excluded following initial telephone screening 
(n=191) or DAWBA results (n=19), and 235 attended a 
baseline assessment and gave informed consent. 
11 candidates were excluded after the further screening 
measures, and 224 participants were enrolled and 
randomly assigned to receive ERP intervention (n=112) or 
psychoeducation (n=112; figure 1). 204 patients received 
the minimum intervention (completing at least the first 
four chapters) and were considered treatment completers 
(99 in the ERP group and 105 in the psychoeducation 
group). In the ERP group, 11 patients were lost to follow-up 
3 months after randomisation, and a further eight patients 
were lost to follow-up 6 months after randomisation. In 
the psychoeducation group, 12 patients were lost to follow-
up 3 months after randomisation, and a further seven were 
lost to follow-up 6 months after randomisation. 186 patients 
were followed up 6 months after randomisation (93 in the 
ERP group and 93 in the psychoeducation group). 
Although participants were reminded about the impor-
tance of masking at each follow-up, four instances of 
allocation concealment breaking were reported to the trial 
manager. In all instances the child disclosed information 
about their treatment to the outcome assessor at the end of 
the follow-up assessment. In these cases, subsequent 
follow-up assessments were done by an alternative, 
masked assessor. All instances were reviewed by the inde-
pendent trial steering committee and data moni toring 
committee for monitoring. The last participant completed 
the 6-month follow-up on April 30, 2020, at which point 
phase 1 of the ORBIT trial was completed.
Baseline characteristics are shown in table 1. 
Participants had a mean age of 12 years, were pre-
dominately male (177 [79%] of 224) and defined their 
ethnicity as White (195 [87%]). Only 30 (13%) participants 
were receiving medication for tics. Premonitory urges 
score at baseline was similar across the groups (mean 
Premonitory Urge for Tics Scale score 22, SD 7 for the 
ERP group and 21, SD 6 for the psychoeducation group), 
equating to medium intensity for premonitory urges. 
Baseline scores on the primary and secondary outcome 
measures were similar across the trial groups (table 2). 
Primary outcome data were available for 99 (88%) of 
112 participants in the intervention group and 105 (94%) 
of 112 participants in the psychoeducation group. The 
only predictor of missingness was site, which was 
included as a covariate in the statistical model.
Mean YGTSS-TTSS at 3 months after randomisation 
was 23·9 (SD 8·2) in the ERP group compared with 
26·8 (7·3) in the psychoeducation group. The mean total 
decrease in YGTSS-TTSS at 3 months was 4·5 (16%, 
SD 1·1) in the ERP group versus 1·6 (6%, 1·0) in the 
psychoeducation group, and at 6 months was 6·9 (24%, 
1·2) in the ERP group versus 3·4 (12%, 1·0) in the 
psychoeducation group. The estimated mean difference 
in YGTSS-TTSS change between the groups at 3 months, 
adjusted for baseline and site, was –2·29 points (95% CI 
–3·86 to –0·71) in favour of ERP, with an effect size of 
–0·31 (95% CI –0·52 to –0·10; table 2).
This adjusted effect on tics increased slightly from 
3 months to 6 months (estimated difference in YGTSS-
TTSS –2·64, 95% CI –4·56 to –0·73; effect size –0·36, 
–0·62 to –0·10). Standardised effect sizes for primary 
and secondary outcomes are shown in figure 2.
The secondary outcome of parent-reported tic 
symptoms (by Parent Tic Questionnaire) supported the 
primary outcome finding at 3 months (estimated 
difference between treatment groups –9·44, 95% CI 
–15·37 to –3·51) and 6 months (–8·60, –14·43 to –2·77). 
There was no statistically significant difference in 
tic-related impairment as measured by the YGTSS 
impairment scale at either timepoint (table 2).
Other secondary outcomes including parent-reported 
general emotional and behavioural functioning, young 
person-reported low mood, and outcome assessor-
reported overall functioning were not significantly 
different between the two groups at 3 or 6 months. 
Although there was no difference in young person- 
 reported anxiety at 3 months, there was a diff erence in 
favour of the ERP group at 6 months (estimated 
difference in Spence Childhood Anxiety Scale –5·10, 
95% CI –9·70 to –0·50). Young person-reported tic-
specific quality of life (C&A-GTS-QOL) and the outcome 
assessor-completed per ception of global improvement 
(CGI-I) showed better results in the ERP group than 
psychoeducation at 3 months (estimated difference in 
C&A GTS-QOL –4·81, 95% CI –8·79 to –0·83; estimated 
difference in CGI-I –0·41; 95% CI –0·71 to –0·11) but 
showed no difference at 6 months.
There were no differences in score on the Mood and 
Feelings Questionnaire or Parent Tic Questionnaire 
at 5 weeks after randomisation (appendix p 26). An 
Psychoeducation (n=112) Exposure and response 
prevention (n=112)
(Continued from previous page)
Taking any medication for tics‡ 16 (13%) 14 (13%)
Centre
Nottingham 57 (51%) 57 (51%)
London 55 (49%) 55 (49%)
Data mean (SD) or n (%). *Comorbidities are based on 50% or greater probability of having a DSM-IV or DSM 5 
diagnosis as assessed by the Development and Wellbeing Assessment. Denominators vary because insufficient 
information was supplied for some participants to make either a positive or negative diagnosis. †Anxiety disorders 
included were separation anxiety, specific phobias, social phobia, panic disorder, agoraphobia, and post-traumatic 
stress disorder. Diagnoses are not mutually exclusive and so percentages are not expected to total 100%. ‡Clonidine, 
risperidone, aripiprazole, haloperidol, guanfacine, or topiramate.
Table 1: Baseline characteristics of participants
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unplanned post-hoc analysis found no evidence that the 
ERP therapy had a different effect in participants with or 
without a comorbid anxiety disorder or with or without 
comorbid ADHD (appendix p 26). An unplanned analysis 
showed a significantly greater posi tive treat ment res-
ponse with ERP at 3 months (patients with CGI-I rating 1 
or 2 [very much or much improved] 36 [36%] of 
101 patients) than with psychoeducation (20 [20%] of 
100 patients, odds ratio [OR] 2·22; 95% CI 1·17–4·20, 
table 3). This superior treatment response was sustained 
at 6 months for ERP (44 [47%] of 93 participants) 
compared with psycho education (27 [29%] of 93 parti -
cipants, OR 2·20; 95% CI 1·20–4·04). There were more 
responders in the ERP group at both timepoints (table 3).
Psychoeducation 
(n=112)








YGTSS-TTSS 28·4 (7.·1) 28·4 (7·7) ·· ··
Secondary outcomes
YGTSS-Impairment 22·9 (9·9) 23·8 (10·3) ·· ··
Parent Tic Questionnaire 53·1 (26·1) 54·7 (29·9) ·· ··
Children’s Global Assessment Scale 72·1 (11·8) 70·7 (13·7) ·· ··
Strengths and Difficulties Questionnaire 16·3 (6·2) 18·0 (6·5) ·· ··
Mood and Feelings Questionnaire 15·9 (11·5) 16·3 (11·3) ·· ··
Spence Child Anxiety Scale* 30·5 (17·9) 32·9 (20·2) ·· ··
C&A-GTS-QOL† 35·0 (17·2) 36·6 (16·4) ·· ··
3 months
Primary outcome
YGTSS-TTSS 26·8 (7·3) 23·9 (8·2) –2·29 (–3·86 to –0·71) –0·31 (–0·52 to –0·10)
Secondary outcomes
Patients analysed for secondary outcomes at 
3 months (n)
101 100 ·· ··
YGTSS-Impairment 19·1 (10·9) 16·7 (10·4) –2·24 (–4·82 to 0·33) ··
Parent Tic Questionnaire 45·7 (25·5) 34·7 (26·4) –9·44 (–15·37 to –3·51) ··
Clinical Global Impression-Improvement 3·37 (1·11) 2·96 (1·1) –0·41 (–0·71 to –0·11) ··
Children’s Global Assessment Scale 75·2 (12·6) 75·9 (12·6) 0·96 (–1·48 to 3·41) ··
Strengths and Difficulties Questionnaire 14·2 (6·3) 14·7 (6·1) –0·38 (–1·62 to 0·85) ··
Mood and Feelings Questionnaire 12·6 (11·1) 10·7 (11·1) –1·36 (–3·75 to 1·02) ··
Spence Child Anxiety Scale 28·2 (18·3) 27·2 (19·0) –2·80 (–6·52 to 0·93) ··
C&A-GTS-QOL† 31·8 (17·7) 25·7 (18·0) –4·81 (–8·79 to –0·83) ··
6 months
Primary outcome
YGTSS-TTSS 25·0 (7·6) 21·5 (8·8) –2·64 (–4·56 to –0·73) –0·36 (–0·62 to –0·10)
Secondary outcomes
Patients analysed for secondary outcomes at 
6 months (n)
93 93 ·· ··
YGTSS-Impairment 17·0 (10·5) 14·7 (10·7) –1·95 (–4·68 to 0·78) ··
Parent Tic Questionnaire 40·6 (24·3) 31·1 (21·6) –8·60 (–14·43 to –2·77) ··
Clinical Global Impression Scale–Improvement 3·1 (1·1) 2·8 (1·3) –0·31 (–0·66 to 0·03) ··
Children’s Global Assessment Scale 76·8 (12·3) 77·5 (14·7) 0·60 (–2·24 to 3·44) ··
Strengths and Difficulties Questionnaire 13·3 (6·1) 15·3 (6·2) 0·57 (–0·93 to 2·07) ··
Mood and Feelings Questionnaire 11·4 (11·2) 11·4 (12·1) –0·61 (–3·85 to 2·64) ··
Spence Child Anxiety Scale 25·9 (18·7) 25·7 (19·6) –5·10 (–9·70 to –0·50) ··
C&A-GTS-QOL† 28·9 (18·3) 27·4 (16·5) –2·91 (–7·60 to 1·78) ··
Data are mean (SD) unless otherwise specified and are calculated for all available data. YGTSS=Yale Global Tic Severity Scale. TTSS=Total Tic Severity Score. C&A-GTS-QOL=Child and 
Adolescent Gilles de la Tourette Syndrome–Quality of Life Scale. Statistical models were adjusted for the baseline measure of the outcome in question (except the Clinical Global 
Impressions Scale-Improvement) and site. For the standardised effect size, YGTSS-TTSS was standardised by the pooled mean and SD at baseline. 3 months after randomisation, 
there were 12 missing observations (11%) for the primary outcome in the Exposure and Response Prevention group compared with 11 (10%) in the psychoeducation group. 
The quantity of missing data for secondary outcomes was similar between groups. *One value missing at baseline. †Higher scores for C&A-GTS-QOL indicate worse quality of life. 
Table 2: Primary and secondary outcome scores at baseline and 3 and 6 months after randomisation
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Two serious adverse events were recorded during the 
trial, affecting two participants in the psychoeducation 
group (one male participant collapsed and was admitted 
to hospital due to a functional movement disorder and 
one female participant attended accident and emergency 
due to a tic attack). Both participants were discharged 
from hospital with no further action. The parents or 
carers of the two participants stated that they did not feel 
the events had been brought on by trial participation, and 
participants had not recently engaged with the internet-
delivered content when the events occurred. Both serious 
adverse events were reviewed by the independent trial 
steering committee and data monitoring committee and 
deemed unrelated to trial participation. Slightly fewer 
adverse events were reported in the ERP group (n=359) 
than in the psychoeducation group (n=431), and fewer 
participants in the ERP group had one or more adverse 
events (88 [79%] of 112 participants) than in the 
psychoeducation group (94 [84%] of 112 participants). The 
most commonly occurring adverse events were low mood, 
increase in tics, and anger or irritability (appendix p 6).
Overall, engagement with the intervention was high 
in both groups, with minimum treatment completion 
(at least four chapters) in 99 (88%) of 112 participants in 
the ERP group and 105 (94%) of 112 participants in the 
psychoeducation group. The number of log-ins were 
similar across both groups, with only slightly more log-
ins for the participants in the ERP group (mean 
difference 7·07, 95% CI 2·27 to 11·88; p=0·02, appendix 
p 7). Perception of treatment suitability and credibility 
was also high across both groups (appendix p 7). Patients 
in the ERP group had a mean of 14·27 minutes more 
therapist time per participant than did patients in 
the psychoeducation group (95% CI –1·80 to 30·36, 
p=0·082), but therapist time required to effectively 
support ERP was low (approximately 2·5 h contact time 
per participant, 15 minutes per week combined child or 
young person and parent or carer contact time).
The fixed yearly cost of delivering the intervention was 
£103·64 per participant (yearly cost of BIP platform 
£8494 and total cost of supervision and training 
£14 719·78). As the interventions were delivered on the 
same platform there was no difference in fixed costs.
There was a small but significant difference between 
the two groups in the variable costs of the platform 
resulting from more platform logins and slightly more 
therapist contact time in the ERP intervention group 
(appendix pp 13–15; table 4). There were no significant 
differences in wider health-care costs (appendix p 16). As 
a combination of the fixed and variable costs and 
including wider health-care costs, delivering the ERP 
intervention cost £159 (95% CI 53–370) more per 
participant than did psychoeducation.
Discussion
Online delivery of therapist-supported ERP is an 
effective treatment of tics in children and adolescents. 
To our knowledge, ORBIT is the first adequately 
powered, randomised, controlled trial assessing ERP for 
tics. ORBIT also represents the largest trial of any 
behavioural treatment for tics and the first trial to 
examine the effectiveness of an online internet-delivered 
behavioural intervention for tics in children and 
adolescents compared with an active control condition. 
The trial recruited ahead of time and target, reflecting a 
substantial unmet treatment need in the population. A 
particular strength of the design was the inclusion of an 
active comparator arm controlling for non-specific 
effects of therapist contact, homework assignments, 
and online access. The uptake of both the ERP and 
psychoeducation was excellent, as was retention to the 
primary outcome at 3 months (90%) and 6 months after 
randomisation (>80%). Acceptability and safety of the 
intervention were high. Analysis of our primary 
outcome (tic severity at 3 months after random 
assignment) indicated a significant effect in favour of 
therapist-supported ERP compared with supported 
psycho education. Importantly, the therapeutic effect 
was durable and even increased slightly at 6 months. 
Figure 2: Standardised effect sizes for primary and secondary outcomes
TTSS=Total Tic Severity Score. YGTSS=Yale Global Tic Severity Scale. PTQ=Parent Tic Questionnaire. CGIS-I=Clinical 
Global Impressions-Improvement. CGAS=Children’s Global Assessment Scale. SDQ=Strengths and Difficulties 
Questionnaire. MFQ=Mood and Feelings Questionnaire. SCAS=Spence Child Anxiety Scale. QoL=Quality of Life. 
C&A-GTS-QOL=Child and Adolescent Gilles de la Tourette Syndrome-Quality of Life Scale.
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Compared with the psychoeducation com parator, 
par ticipants were twice as likely to show a positive 
treatment response with the ERP intervention.
The participants in this trial had moderate to severe 
baseline tic severity, which was approximately 0·5 SD 
higher than reported in previous face-to-face behavioural 
treatment trials.2,5 The trial design minimised the clinical 
comorbidity exclusions, resulting in a sample broadly 
representative of real-world clinical practice, and inclu ded 
participants with autism spectrum disorder, a group 
usually excluded in similar behavioural intervention 
trials. In the behavioural intervention group, just under a 
third had a coexisting anxiety disorder and just under a 
quarter had ADHD. The reduction in tics associated with 
the behavioural intervention was similar in those with 
and without co-existing anxiety or ADHD diagnoses.
In our previous systematic review2 of tic treatments in 
children and adolescents, we identified two superiority 
trials2,4 of face-to-face behavioural therapy (HRT or CBIT) 
for tics that reported a medium effect in improving tics 
in favour of behavioural therapy compared with waitlist 
or supportive psychotherapy (pooled effect size 0·64, 
95% CI 0·29–0·99). The magnitude of effect of this 
online ERP in the current trial is about half that reported 
from previous superiority trials of face-to-face HRT or 
CBIT for tics.2 However, it is difficult to make direct 
comparisons of therapeutic efficacy with previous trials 
of face-to-face behavioural therapy given that this trial 
had higher baseline tic severity, fewer comorbidity 
exclusions, a lower proportion of participants receiving 
tic medication, longer follow-up, and a potent active 
comparator. In practice, direct comparison of efficacy 
might also be misleading with respect to implementation 
because the purpose is not to replace face-to-face therapy, 
but to allow this scarce resource to be better targeted to 
those who need it most, and to offer an effective digitally 
enabled intervention to a much larger population of 
children and adolescents who are unable to access any 
behavioural treatment for tics.
A major difference between online delivery and face-to-
face behavioural therapy for tics is the reduced amount of 
therapist time, the required skill level of the therapist, and 
cost. The total therapist contact time in this trial was 
around 2·5 h compared with 9–10 h in comparable 
Psychoeducation Exposure and response 
prevention 
Odds ratio (95% CI)
Baseline 
Patients randomly assigned 112 112 ··
3 months
Patients with available follow-up data 100 101 ··
CGI-I score indicating much or very much improved (responded to treatment) 20 (20%)  36 (36%) 2·22 (1·17–4·20)
6 months
Patients with available follow-up data 93 93 ··
CGI-I score indicating much or very much improved (responded to treatment) 27 (29%) 44 (47%) 2·20 (1·20–4·04)
Change in response between 3 and 6 months
Patients with available follow-up data 93 90 ··
No response to treatment at either time 56 (60%) 37 (41%) ··
Response at both times 9 (10%) 23 (26%) ··
New responder at 6 months 18 (19%) 20 (22%) ··
Relapsed responder at 6 months 10 (11%) 10 (11%) ··
Data are n or n (%). Statistical models were adjusted for site. Percentages are calculated by how many participants were still being followed up at each timepoint and for 
whom follow-up data were available (ie, completion of questionnaires or outcome measures). CGI-I=Clinical Global Impressions–Improvement.








Cost of therapist contact time
Young person £16 (9) £18 (9) ··
Parent or carer 1 £22 (10) £25 (13) ··
Parent or carer 2 £0·09 (0·56) £0·20 (2) ··




Young person £3 (1) £3 (2) ··
Parent or carer 1 £3 (2) £3 (2) ··
Parent or carer 2 £0·01 (0·10) £0·04 (0·33) ··
Total £6 (3) £7 (4) £1·25 
(0·46–2·04), 
p=0·00
Total variable costs £44 (18) £50 (22) £6·27 
(0·88–11·67), 
p=0·02
Data are mean (SD) or estimated difference (95% CI). *One patient in each group 
had no therapist time.
Table 4: Variable costs between the psychoeducation and exposure and 
response prevention groups across 6 months
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evidence-based face-to-face behavioural therapy for tics. 
Given the shortage of highly trained therapists with 
expertise in tic disorders and scarce access to behavioural 
therapy, online delivery of ERP for tics has the potential 
to greatly expand the reach of effective behavioural 
interventions. With more efficient use of therapist time it 
should be possible to treat four people for every one person 
treated with face-to-face therapy. Moreover, the lower level 
of experience required in therapists to support online 
behavioural therapy should expand the potential pool 
of therapists and thereby further extend availability. A 
strength of the online delivery model is that fidelity of 
therapeutic content is built into the intervention, making 
transfer to real-world effectiveness much less susceptible 
to therapeutic drift and the skill level of individual 
therapists than in traditional face-to-face therapy.
The study has several limitations. First, it is the first 
adequately powered trial of therapist-supported, online 
ERP, and replications are required. Second, it is not 
possible in this trial to separate the effects of digital 
online delivery and ERP. In future, clinical and cost-
effectiveness comparisons of digital online versus 
face-to-face ERP or CBIT will be needed. Third, some 
people do not have sufficient access to the internet and 
smartphones, which could have limited the reach of 
this internet-delivered ERP intervention. Although this 
does not appear to be an issue in the UK, wherein 
90% of households have access to the internet and 
98% of young people own a smartphone,32 it could be 
an important consideration when generalising these 
findings to other countries or populations with less 
access. Fourth, a large proportion of the sample was 
White, which could limit the generalisability of the 
findings with regards to ethnicity. Fifth, the amount of 
tic medication use and co-morbid obsessive compulsive 
disorder diagnoses were lower than in comparable 
studies done in the USA, which might limit gen-
eralisability to these populations. Finally, although tic 
severity in ORBIT is higher than in comparable studies, 
the findings might not be generalisable to those young 
people with tics outside the severity range of this study 
population.
Implementation research will be required to establish 
how best to integrate online behavioural therapy for tics 
within treatment pathways. For example, digital or online 
delivery might work best as a first-line behavioural 
intervention, with non-responders or poor responders 
being stepped-up to more intensive face-to-face therapy. 
Another model to evaluate would be the blending of 
online and face-to-face therapy for more complex cases, 
thereby reducing the overall number of face-to-face 
sessions required.
Evidence from this trial suggests that online therapist-
supported ERP is an effective behavioural therapy for 
reduction in tic symptoms which has the potential to 
greatly increase the availability of effective behavioural 
treatment for children and adolescents with tic disorders.
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